Science Explorer Back to mapMap
Discussion
Topic · Pathology and Forensic Medicine

Tumors and Oncological Cases

Tumors and Oncological Cases is a research topic within Pathology and Forensic Medicine. Science Explorer counts 27k research works in it since 1950. 10.1% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the clinical and pathological characteristics, immunohistochemical assessment, and diagnostic challenges of granular cell tumors in various anatomical locations such as the breast, oral cavity, soft tissues, and gastrointestinal tract. It also discusses the distinction between benign and malignant granular cell tumors, along with their unique histological features.

  • Granular Cell Tumor
  • Immunohistochemical Assessment
  • Clinical Correlation
  • S100 Protein
  • Ki-67 Proliferative Index
  • Malignant Granular Cell Tumor
  • Soft Tissues
  • Breast
  • Oral Cavity
  • Pathological Characteristics
Research works
27k
fractional, since 1950
In the world top 10%
2.7k
per year above
Top-10% rate
10.1%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
-4%
the tick is no change
Largest producer
United States
29% of the 10 largest, 2022-now
Tumors and Oncological Cases

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Tumors and Oncological Cases research?

By volume, the United States and India publish the most (810 and 582 works in 2022-now).

By volume, 2022-now

  1. 1 United States 810 works
  2. 2 India 582 works
  3. 3 China 376 works
  4. 4 Japan 257 works
  5. 5 Brazil 178 works
  6. 6 Germany 129 works
  7. 7 Italy 119 works
  8. 8 United Kingdom 111 works
  9. 9 Spain 105 works
  10. 10 Türkiye 96 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

United States: 29.3%India: 21.1%China: 13.6%Japan: 9.3%6 others listed: 26.7%29%largest
United States810 · 29.3%India582 · 21.1%China376 · 13.6%Japan257 · 9.3%6 others listed739 · 26.7%

Shares of the rows listed above, not of the whole node.

Which institutions lead Tumors and Oncological Cases research?

By volume in 2022-now, All India Institute of Medical Sciences publishes the most Tumors and Oncological Cases research, followed by Harvard University and Mayo Clinic.

By volume, 2022-now

  1. 1 All India Institute of Medical SciencesIndia 62 works
  2. 2 Harvard UniversityUnited States 28 works
  3. 3 Mayo ClinicUnited States 24 works
  4. 4 Sichuan UniversityChina 20 works
  5. 5 Mohammed V UniversityMorocco 19 works
  6. 6 Capital Medical UniversityChina 18 works
  7. 7 Shanghai Jiao Tong UniversityChina 18 works
  8. 8 Zhejiang UniversityChina 15 works
  9. 9 University of DelhiIndia 15 works
  10. 10 Post Graduate Institute of Medical Education and ResearchIndia 14 works

Who are the leading researchers in Tumors and Oncological Cases?

The most-cited researchers publishing on Tumors and Oncological Cases include Bert Vogelstein, John Q. Trojanowski and Matthew M. Meyerson.

  1. 1 Bert Vogelstein United States 373k citations
  2. 2 John Q. Trojanowski United States 286k citations
  3. 3 Matthew M. Meyerson United States 280k citations
  4. 4 Hagop M. Kantarjian United States 273k citations
  5. 5 Jean‐Louis Vincent Belgium 262k citations
  6. 6 Hans C. Clevers Netherlands 260k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Tumors and Oncological Cases?

The most cited paper in Tumors and Oncological Cases is "Case report 3" (Murray K. Dalinka, R. E. Brennan, Arthur S. Patchefsky, 1976), with 4,090 citations. Next come "“Field cancerization” in oral stratified squamous epithelium. Clinical implications of multicentric origin" (3,563) and "Prediction of central nervous system embryonal tumour outcome based on gene expression" (2,395).

Most cited papers
#PaperReleasedCitations
1 Case report 3 Murray K. Dalinka, R. E. Brennan, Arthur S. Patchefsky · Skeletal Radiology 1976 4,090
2 “Field cancerization” in oral stratified squamous epithelium. Clinical implications of multicentric origin Danely P. Slaughter, Harry W. Southwick, Walter Smejkal · Cancer Open access Sep 1953 3,563
3 Prediction of central nervous system embryonal tumour outcome based on gene expression Scott L. Pomeroy et al. · Nature 2002 2,395
4 Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma Andrew D. Rhim, Paul E. Oberstein, Dafydd Thomas et al. · Cancer Cell Open access 22 May 2014 2,087
5 Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours Olivier Delattre, Jessica Zucman‐Rossi, Béatrice Plougastel-Douglas et al. · Nature Sep 1992 1,928
All 100 most cited papers, with filters and sorting

Where is Tumors and Oncological Cases research done?

The largest centres of Tumors and Oncological Cases research in 2022-now are New Delhi (India), Beijing (China), Tokyo (Japan) and Chennai (India). Among places with at least 20 works in it, it is an unusually large share of all research in Rabat.

Largest cities, 2022-now

  1. 1 New DelhiIndia 67 works
  2. 2 BeijingChina 50 works
  3. 3 TokyoJapan 49 works
  4. 4 ChennaiIndia 40 works
  5. 5 New YorkUnited States 39 works
  6. 6 LondonUnited Kingdom 36 works
  7. 7 MoscowRussia 36 works
  8. 8 São PauloBrazil 36 works
  9. 9 ShanghaiChina 34 works
  10. 10 MumbaiIndia 33 works

Where it is the local speciality

  1. RabatMA · 21.7 works8.7×
← less than its size predicts1×more →

Location quotient: how much more of its research is in Tumors and Oncological Cases than the world average.

See Tumors and Oncological Cases on the map

Where is the best place to study Tumors and Oncological Cases?

Among universities, judged by research, Harvard University, All India Institute of Medical Sciences and University of Toronto score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%20%40%mean 19.94%fractional works in this field (log) →share of work in the world top 10% →University of TorontoHarvard UniversityJohns Hopkins Univer…All India Institute …
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Harvard UniversityUnited States 64.928.1%2.6×28 -24.9%
2All India Institute of Medical SciencesIndia 55.64.0%16.3×62 +57.7%
3University of TorontoCanada 55.238.5%1.5×11 -33.1%
4Johns Hopkins UniversityUnited States 49.919.4%1.9×10 +18.1%
5Shanghai Jiao Tong UniversityChina 46.213.5%1.8×18 +42.9%
6Sichuan UniversityChina 45.713.0%2.6×20 +77.5%
7Stanford UniversityUnited States 44.727.3%1.9×10 -11.2%
8University of PennsylvaniaUnited States 44.224.8%3.0×11 -7.6%
9Sun Yat-sen UniversityChina 42.120.6%1.5×10 +42.0%
10Capital Medical UniversityChina 39.710.2%4.8×18 +6.4%

Universities only. The score blends excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Tumors and Oncological Cases, country by country

Is Tumors and Oncological Cases research growing?

Output in 2022-2025 was 4% lower than in 2018-2021, peaking in 2021.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Tumors and Oncological Cases as a percentage of every work published that year, 0.020% in 2024.

still counting0.020%0.040%0.060%Tumors and Oncological Cases0.014% in 202519801990200020102020

Fractional works of Tumors and Oncological Cases over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Tumors and Oncological Cases10.3% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Tumors and Oncological Cases. Posts are plain text and can be reported.